Cargando…
Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
Inflammatory breast cancer (IBC) is a rare type of breast cancer that is associated with poor outcomes compared with non-IBC. Overexpression of HER2 is enriched in IBC, and those with HER2-positive disease have a relatively favorable prognosis, with improved survival over the last two decades driven...
Autores principales: | Ge, Jennifer Y., Overmoyer, Beth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299395/ https://www.ncbi.nlm.nih.gov/pubmed/34326744 http://dx.doi.org/10.1159/000516760 |
Ejemplares similares
-
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2023) -
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors
por: Weide, Rudolf, et al.
Publicado: (2014) -
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
por: Chen, I-Chun, et al.
Publicado: (2021) -
HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020) -
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer
por: Pernas, Sonia, et al.
Publicado: (2022)